- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Bristol Myers Squibb Shares Acquired by Vinva Investment Management
Hedge fund boosts stake in biopharmaceutical company by 140% in Q3
Published on Mar. 8, 2026
Got story updates? Submit your updates here. ›
Vinva Investment Management Ltd. significantly increased its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 140.3% in the third quarter, according to a recent 13F filing with the SEC. The fund now owns 584,506 shares of the biopharmaceutical company's stock, valued at $25.8 million.
Why it matters
Bristol Myers Squibb is a major player in the pharmaceutical industry, known for its oncology and immunology drug portfolios. This sizable increase in ownership by Vinva Investment Management suggests the hedge fund sees significant potential in the company's future performance and growth prospects.
The details
Vinva Investment Management added 341,246 shares of Bristol Myers Squibb to its portfolio during the third quarter, bringing its total holdings to 584,506 shares. This represents a 140.3% increase from the previous quarter. The hedge fund's increased stake in BMY is part of a broader investment strategy focused on the biopharmaceutical sector.
- Vinva Investment Management filed its 13F report for the third quarter of 2026.
The players
Vinva Investment Management Ltd.
A hedge fund that manages investments in various sectors, including the biopharmaceutical industry.
Bristol Myers Squibb Company
A global biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases, with a strong emphasis on oncology and immunology.
The takeaway
Vinva Investment Management's significant increase in its Bristol Myers Squibb holdings suggests the hedge fund sees strong growth potential in the biopharmaceutical company's pipeline and future performance. This move highlights the continued investor interest in the pharmaceutical industry, particularly in companies with robust drug portfolios and promising drug development programs.
